Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay on the NeuMoDx™ Molecular Systems

NCT05162547 is registered in ClinicalTrials.gov with QIAGEN Gaithersburg, Inc as lead sponsor.

NCT NCT05162547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay on the NeuMoDx™ Molecular Systems
Lead sponsor
QIAGEN Gaithersburg, Inc
Phase
Observational
Overall status
Completed
Start date
March 11, 2022
Completion date
February 7, 2024
Enrollment
2,383 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory disease